Form 4: Veracyte CFO Rebecca Chambers Sells Shares Under 10b5-1 Plan

Rebecca Chambers, CFO of Veracyte, Inc., sold 527 shares of common stock at $43.85 per share on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 3, 2025, Rebecca Chambers, the Chief Financial Officer of Veracyte, Inc. (VCYT), sold 527 shares of the company's common stock.
• The sale was executed at a price of $43.85 per share.
• Following the transaction, Chambers directly owns 113,510 shares of Veracyte common stock.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. Rule 10b5-1 plans allow insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a company insider could potentially create uncertainty among shareholders, although the impact is likely minimal given the small number of shares sold and the existence of a pre-arranged trading plan.

Key Dates

Keywords

Veracyte, VCYT, Rebecca Chambers, CFO, Form 4, Stock Sale, Rule 10b5-1, Insider Trading